Andreas Lohri

6.0k total citations · 1 hit paper
69 papers, 2.8k citations indexed

About

Andreas Lohri is a scholar working on Pathology and Forensic Medicine, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Andreas Lohri has authored 69 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Pathology and Forensic Medicine, 32 papers in Oncology and 29 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Andreas Lohri's work include Lymphoma Diagnosis and Treatment (44 papers), Lung Cancer Treatments and Mutations (20 papers) and Chronic Lymphocytic Leukemia Research (13 papers). Andreas Lohri is often cited by papers focused on Lymphoma Diagnosis and Treatment (44 papers), Lung Cancer Treatments and Mutations (20 papers) and Chronic Lymphocytic Leukemia Research (13 papers). Andreas Lohri collaborates with scholars based in Switzerland, Germany and Austria. Andreas Lohri's co-authors include Volker Diehl, Dirk Hasenclever, Beate Pfistner, F. Boissevain, Matthias W. Haenel, Susanne Decker, R. Zschaber, Peter E. Müller, Hartmut Kirchner and Angelo Michele Carella and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

Andreas Lohri

65 papers receiving 2.8k citations

Hit Papers

Aggressive conventional chemotherapy compared with high-d... 2002 2026 2010 2018 2002 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial
    2002 755 citations Andreas Lohri, Dirk Hasenclever et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Andreas Lohri Switzerland 24 2.1k 1.5k 735 723 521 69 2.8k
Catherine Sebban France 24 2.3k 1.1× 1.8k 1.2× 862 1.2× 575 0.8× 405 0.8× 68 3.0k
Karamjit Gill Canada 13 2.4k 1.2× 1.6k 1.1× 859 1.2× 636 0.9× 292 0.6× 19 2.9k
Hervé Ghesquières France 31 2.1k 1.0× 1.6k 1.1× 852 1.2× 877 1.2× 274 0.5× 193 3.0k
Max Wolf Australia 22 1.7k 0.8× 1.0k 0.7× 791 1.1× 490 0.7× 275 0.5× 55 2.1k
Frederick Hagemeister United States 27 2.3k 1.1× 1.7k 1.2× 1.0k 1.4× 470 0.7× 603 1.2× 69 3.3k
Y Bastion France 23 2.5k 1.2× 1.6k 1.1× 1.2k 1.6× 613 0.8× 346 0.7× 47 3.2k
Paul A. Hamlin United States 33 2.9k 1.4× 2.0k 1.4× 925 1.3× 914 1.3× 521 1.0× 155 4.0k
Caterina Stelitano Italy 32 3.0k 1.5× 1.4k 0.9× 1.1k 1.5× 1.3k 1.8× 851 1.6× 114 3.8k
Luigi Rigacci Italy 28 3.1k 1.5× 1.6k 1.1× 809 1.1× 974 1.3× 798 1.5× 144 4.0k
Karim Belhadj France 25 2.3k 1.1× 1.6k 1.1× 779 1.1× 704 1.0× 468 0.9× 101 3.6k

Countries citing papers authored by Andreas Lohri

Since Specialization
Citations

This map shows the geographic impact of Andreas Lohri's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andreas Lohri with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andreas Lohri more than expected).

Fields of papers citing papers by Andreas Lohri

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andreas Lohri. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andreas Lohri. The network helps show where Andreas Lohri may publish in the future.

Co-authorship network of co-authors of Andreas Lohri

This figure shows the co-authorship network connecting the top 25 collaborators of Andreas Lohri. A scholar is included among the top collaborators of Andreas Lohri based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andreas Lohri. Andreas Lohri is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Moccia, Alden A., Christian Taverna, Sämi Schär, et al.. (2020). Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trial. Blood Advances. 4(23). 5951–5957. 17 indexed citations
2.
Cogliatti, Sergio, Mario Bargetzi, Francesco Bertoni, et al.. (2016). Supplementum 216: Diagnosis and treatment of marginal zone lymphoma. Swiss Medical Weekly. 146(3132). 216–216. 2 indexed citations
3.
Kasenda, Benjamin, Dieter Koeberle, Bernhard C. Pestalozzi, et al.. (2014). Survival in overweight patients with advanced pancreatic carcinoma: a multicentre cohort study. BMC Cancer. 14(1). 728–728. 37 indexed citations
4.
Taverna, Christian, Giovanni Martinelli, Felicitas Hitz, et al.. (2013). Rituximab Maintenance Treatment For a Maximum Of 5 Years In Follicular Lymphoma: Results Of The Randomized Phase III Trial SAKK 35/03. Blood. 122(21). 508–508. 7 indexed citations
5.
Rothe, Achim, Stephanie Sasse, Helen Goergen, et al.. (2012). Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience. Blood. 120(7). 1470–1472. 60 indexed citations
6.
Sasse, Stephanie, Beate Klimm, Helen Görgen, et al.. (2012). Comparing long-term toxicity and efficacy of combined modality treatment including extended- or involved-field radiotherapy in early-stage Hodgkin's lymphoma. Annals of Oncology. 23(11). 2953–2959. 25 indexed citations
7.
Forrer, Flavio, et al.. (2012). Is there need for radioimmunotherapy? results of a phase I/II study in patients with indolent B-cell lymphomas using lutetium-177-DOTA-rituximab.. PubMed. 56(6). 544–50. 7 indexed citations
8.
Hitz, Felicitas, Andreas Lohri, Christian Taverna, et al.. (2012). Diagnosis and treatment of diffuse large B-cell lymphoma. Swiss Medical Weekly. 142(506). w13511–w13511. 25 indexed citations
9.
10.
Renner, Christoph, Pier Luigi Zinzani, Rémy Gressin, et al.. (2012). A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. Haematologica. 97(7). 1085–1091. 77 indexed citations
11.
Martinelli, Giovanni, Shu-Fang Hsu Schmitz, Thomas Cerny, et al.. (2010). Long-Term Follow-Up of Patients With Follicular Lymphoma Receiving Single-Agent Rituximab at Two Different Schedules in Trial SAKK 35/98. Journal of Clinical Oncology. 28(29). 4480–4484. 168 indexed citations
12.
13.
Engert, Andreas, Volker Diehl, Jeremy Franklin, et al.. (2009). Escalated-Dose BEACOPP in the Treatment of Patients With Advanced-Stage Hodgkin's Lymphoma: 10 Years of Follow-Up of the GHSG HD9 Study. Journal of Clinical Oncology. 27(27). 4548–4554. 303 indexed citations
14.
Forrer, Flavio, Melpomeni Fani, P. Powell, et al.. (2009). In vitro characterization of 177Lu-radiolabelled chimeric anti-CD20 monoclonal antibody and a preliminary dosimetry study. European Journal of Nuclear Medicine and Molecular Imaging. 36(9). 1443–1452. 48 indexed citations
15.
Buser, Andreas, M. Stern, Michael Medinger, et al.. (2008). Impaired B-cell reconstitution in lymphoma patients undergoing allogeneic HSCT: an effect of pretreatment with rituximab?. Bone Marrow Transplantation. 42(7). 483–487. 16 indexed citations
16.
17.
Landmann, Christine, Roger Kann, Jakob Passweg, et al.. (2000). Combined chemoradiotherapy with daily low-dose cisplatin in locally advanced inoperable non-small cell lung cancer. Radiotherapy and Oncology. 56(2). 169–173. 7 indexed citations
18.
Hille, B van, et al.. (1997). Assessment of drug-induced dysregulations among seven resistance-associated genes in human tumour cell lines.. PubMed. 16(6B). 3531–6. 12 indexed citations
19.
20.
Lohri, Andreas & Joseph M. Connors. (1994). Identification of Risk Factors in Patients Treated for First Relapse of Hodgkin's Disease. Leukemia & lymphoma. 15(3-4). 189–200. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Catherine Sebban Breakdown of academic impact, for papers by Karamjit Gill Breakdown of academic impact, for papers by Hervé Ghesquières Breakdown of academic impact, for papers by Max Wolf Breakdown of academic impact, for papers by Frederick Hagemeister Breakdown of academic impact, for papers by Y Bastion Breakdown of academic impact, for papers by Paul A. Hamlin Breakdown of academic impact, for papers by Caterina Stelitano Breakdown of academic impact, for papers by Luigi Rigacci Breakdown of academic impact, for papers by Karim Belhadj
Rankless by CCL
2026